A Phase Ib Study of ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed Chronic Lymphocytic Leukemia
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2017
At a glance
- Drugs Ibrutinib (Primary) ; Idelalisib (Primary) ; Ricolinostat (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 25 May 2017 Status changed from recruiting to active, no longer recruiting.
- 16 Nov 2016 Status changed from not yet recruiting to recruiting.
- 04 Jun 2016 New trial record